These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 24174581

  • 1. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.
    Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D.
    Neurology; 2013 Nov 19; 81(21):1856-63. PubMed ID: 24174581
    [Abstract] [Full Text] [Related]

  • 2. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R, Multiple Sclerosis Outcome Assessments ConsortiumMultiple Sclerosis Outcome Assessments Consortium (MSOAC), Critical Path Institute, Tucson, AZ, USA..
    Mult Scler; 2017 Apr 19; 23(5):704-710. PubMed ID: 28206828
    [Abstract] [Full Text] [Related]

  • 3. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
    Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D.
    Mult Scler; 2017 Sep 19; 23(10):1405-1414. PubMed ID: 27903937
    [Abstract] [Full Text] [Related]

  • 4. The six spot step test: a new measurement for walking ability in multiple sclerosis.
    Nieuwenhuis MM, Van Tongeren H, Sørensen PS, Ravnborg M.
    Mult Scler; 2006 Aug 19; 12(4):495-500. PubMed ID: 16900764
    [Abstract] [Full Text] [Related]

  • 5. A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients.
    Phan-Ba R, Calay P, Grodent P, Delrue G, Lommers E, Delvaux V, Moonen G, Nagels G, Belachew S.
    NeuroRehabilitation; 2012 Aug 19; 30(4):261-6. PubMed ID: 22672939
    [Abstract] [Full Text] [Related]

  • 6. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI, Sobieraj DM, Marinucci LN.
    Curr Med Res Opin; 2012 Jan 19; 28(1):49-56. PubMed ID: 22073939
    [Abstract] [Full Text] [Related]

  • 7. Utility of the Six-Spot Step Test as a Measure of Walking Performance in Ambulatory Individuals With Multiple Sclerosis.
    Fritz NE, Jiang A, Keller J, Zackowski KM.
    Arch Phys Med Rehabil; 2016 Apr 19; 97(4):507-512. PubMed ID: 26577146
    [Abstract] [Full Text] [Related]

  • 8. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
    Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.
    Neurology; 2013 Apr 16; 80(16):1509-17. PubMed ID: 23535489
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D.
    Eur J Neurol; 2015 Mar 16; 22(3):570-7. PubMed ID: 25511792
    [Abstract] [Full Text] [Related]

  • 10. Does disability level impact the relationship of muscle strength to walking performance in people with multiple sclerosis? a cross-sectional analysis.
    Mañago MM, Callesen J, Dalgas U, Kittelson J, Schenkman M.
    Mult Scler Relat Disord; 2020 Jul 16; 42():102052. PubMed ID: 32240963
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.
    Phan-Ba R, Pace A, Calay P, Grodent P, Douchamps F, Hyde R, Hotermans C, Delvaux V, Hansen I, Moonen G, Belachew S.
    Neurorehabil Neural Repair; 2011 Sep 16; 25(7):672-9. PubMed ID: 21436388
    [Abstract] [Full Text] [Related]

  • 12. Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic.
    Bethoux FA, Palfy DM, Plow MA.
    Int J Rehabil Res; 2016 Jun 16; 39(2):134-9. PubMed ID: 26926380
    [Abstract] [Full Text] [Related]

  • 13. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS.
    Bosma L, Kragt JJ, Polman CH, Uitdehaag BM.
    Mult Scler; 2013 Mar 16; 19(3):326-33. PubMed ID: 22907939
    [Abstract] [Full Text] [Related]

  • 14. The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Kalinowski A, Cutter G, Bozinov N, Hinman JA, Hittle M, Motl R, Odden M, Nelson LM.
    Mult Scler; 2022 Feb 16; 28(2):289-299. PubMed ID: 34100297
    [Abstract] [Full Text] [Related]

  • 15. Quantitative Synthesis of Timed 25-Foot Walk Performance in Multiple Sclerosis.
    Sikes EM, Cederberg KL, Sandroff BM, Bartolucci A, Motl RW.
    Arch Phys Med Rehabil; 2020 Mar 16; 101(3):524-534. PubMed ID: 31669296
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
    Helmlinger B, Pinter D, Hechenberger S, Bachmaier G, Khalil M, Heschl B, Damulina A, Pichler A, Enzinger C.
    J Neurol Sci; 2024 Jul 15; 462():123073. PubMed ID: 38852261
    [Abstract] [Full Text] [Related]

  • 17. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.
    Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH.
    Mult Scler; 2006 Oct 15; 12(5):594-8. PubMed ID: 17086905
    [Abstract] [Full Text] [Related]

  • 18. Further validation of the Six-Spot Step Test as a measure of ambulation in multiple sclerosis.
    Sandroff BM, Motl RW, Sosnoff JJ, Pula JH.
    Gait Posture; 2015 Jan 15; 41(1):222-7. PubMed ID: 25455207
    [Abstract] [Full Text] [Related]

  • 19. Reliability parameters of the Timed 25-Foot-Walk (T25FW) in patients with Multiple Sclerosis: Lower walking speed is associated with greater Smallest Detectable Change.
    Oosterveer DM, Wouda NC, Volker G, van den Berg C, Terluin B, Hoitsma E.
    Mult Scler Relat Disord; 2024 Aug 15; 88():105731. PubMed ID: 38924934
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
    Skov CD, Sørensen CB, Thorning M, Lambertsen KL, Frich LH, Jensen HB, Holsgaard-Larsen A, Nielsen HH.
    Mult Scler Relat Disord; 2022 Oct 15; 66():104034. PubMed ID: 35843140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.